BriaCell issues placement agent warrants exercisable from June 2026

BriaCell Therapeutics filed a warrant agreement allowing placement agents to purchase common shares starting June 2, 2026, expiring five years later per FINRA rules. The warrant issuance is typical financing activity for biotech companies seeking to incentivize capital raising intermediaries.